As the cannabis, hemp, and CBD space starts to heat back up, traders and investors are looking for emerging trends that could represent the new spark that lights the fire again among the larger retail investment public. One distinct possibility in that narrative is the cannabis-infused beverage space.
A recent report by Grand View Research said that the global cannabis beverages market size is expected to reach $2.8 Billion by 2025 at a CAGR of 17.8%.
According to the report, “By component, the market is segmented into Cannabidiol (CBD) and Tetrahydrocannabinol (THC). The demand of THC infused cannabis beverages is majorly driven by rising product demand from adult consumers for recreational purposes. Rising demand for the therapeutic effects of the component along with the euphoria it provides is expected to bode well for the growth of the segment in the forthcoming years.”
Active companies in the cannabis-infused beverage market include: Aphria Inc. (NYSE:APHA) (TSX:APHA), CV Sciences, Inc. (OTCQB:CVSI), Cannabis Global, Inc. (OTCMKTS:MCTC), and Hexo Corp (NYSE:HEXO) (TSX:HEXO).
Aphria Inc (NYSE:APHA) produces, supplies, and sells medical cannabis in Canada. Its cannabis products include dried flowers and cannabis oils. APHA sells its products through its online store and telephone orders, as well as MMPR licensed producers.
APHA is also becoming a leader in the emerging cannabis beverages market.
The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders.
The company sells its products through its online store or phones, as well as engages in the wholesale shipping of medical marijuana plant cuttings and dried buds to other licensed producers. Aphria Inc. is headquartered in Leamington, Canada.
Shares acting well over the past five days, up about 18% in that timeframe.
Aphria Inc (NYSE:APHA) managed to rope in revenues totaling $144.4M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 96.3%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($515.1M against $178.1M).
CV Sciences Inc (OTCMKTS:CVSI) bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.
CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.
Moreover, CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.
The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
Shares of the stock have powered higher over the past month, rallying roughly 65% in that time on strong overall action.
CV Sciences Inc (OTCMKTS:CVSI) pulled in sales of $8.3M in its last reported quarterly financials, representing top line growth of -44.5%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($7.6M against $12.5M, respectively).
MCTC Holdings Inc (OTCMKTS:MCTC), now doing business as Cannabis Global, Inc. (MCTC), is a more speculative play in the space, but recently put out news that suggests it has the potential to make big waves in the cannabis-infused beverage marketplace.
Specifically, the company just announced it has completed product development and has begun distribution of its unique tetrahydrocannabivarin (THC-V) coffee and tea products to product beta testers.
According to the release, “Cannabis Global has integrated three internally developed technologies into the unique manufacturing process for the industry’s first THC-V beverages. The first of these is the process developed by the Company to produce 70%+ loaded THC-V, controlled release, nanoparticles utilizing laboratory-based, pharmaceutical-grade production equipment. The Company is also utilizing both its internally developed powerization and one step dosing system, ensuring precise dosing and significantly faster production. The Company has filed provisional patents on all three technologies.”
Cannabis Global (OTCMKTS:MCTC) has recently filed six patents on cannabinoid extraction technologies and delivery systems. Management is currently working with patent counsel to protect various other technologies it has developed or is currently developing, including its programs pertaining to cannabinoid glycosides, polymeric cannabinoid nanoparticles and nanofibers, and its hemp extract-based alcohol replacement technologies.
“Our unique infusion and production technologies provide Cannabis Global with a product purity advantage as well as a clear path to low cost leadership,” commented CEO Arman Tabatabaei. “The THC-V cannabinoids are synthesized and entirely free of impurities. While there were some upfront technology development and intellectual property protection costs, we expect our ongoing variable production costs to be less than half of any potential competitor. Via our technologies, we turn one of the cannabis industry’s most expensive items – pure THC-V cannabinoids – into a cost-effective solution that sets a new standard for product purity in the cannabinoid-based products marketplace.”
MCTC Holdings Inc (OTCMKTS:MCTC) had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($157K against $1.5M, respectively).
Hexo Corp (NYSE:HEXO) trumpets itself as a company that, through its subsidiaries, produces, markets, and sells cannabis in Canada.
It offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. The company is also partnered up with Molson Coors (TAP) to make a big splash in the cannabis-infused beverage space.
The company offers its adult-use and medical products under the HEXO brand name. HEXO Corp. is headquartered in Gatineau, Canada.
The context for this stock is a bit of a bid, with shares acting well over the past five days, up about 28% in that timeframe. Shares of the stock have powered higher over the past month, rallying roughly 28% in that time on strong overall action.
Hexo Corp (NYSE:HEXO) managed to rope in revenues totaling $17M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 26.6%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($105.7M against $68.2M).